Molecular Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Cost reduction program will include laying off 33 of the company's 56 employees and discontinuing development for its MB840 liver imaging agent to save $5 mil. annually, the company announces March 30. The move follows Palatin Technologies' March 14 decision not to proceed with a planned merger between the two imaging agent developers (1"The Gray Sheet" March 20, p. 15). MBI plans to focus solely on its Optison imaging agent
You may also be interested in...
Molecular Biosystems Weighing Options After Palatin Exits Merger Talks
Molecular Biosystems, Inc. is exploring alternatives to a previously planned merger with Palatin Technologies and expects to reach a decision by mid-April, following Palatin's March 14 decision not to proceed with the deal. Options under consideration include remaining independent or looking for another merger partner, MBI says.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.